New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.

  • Marc Thill
  • Published 2015 in Expert review of anticancer therapy


Trastuzumab is a highly successful monoclonal antibody (mAb) that has been used primarily for the treatment of HER2-positive breast cancer. Because of its success and its impending patent expiry in Europe in 2014, a number of copy versions of trastuzumab have been developed and are currently undergoing a comparability exercise for marketing authorization… (More)
DOI: 10.1586/14737140.2015.993318


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.


Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.